BIA 3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of l-DOPA to the brain and reduces its O-methylation
- 1 May 2001
- journal article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 420 (1) , 27-32
- https://doi.org/10.1016/s0014-2999(01)01020-2
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Tolcapone in stable Parkinson's disease: Efficacy and safety of long-term treatmentNeurology, 1997
- Effects of tolcapone in Parkinson's patients taking L‐dihydroxyphenylalanine/carbidopa and selegilineMovement Disorders, 1995
- Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-DOPA and dopamine in ratsEuropean Journal of Pharmacology, 1995
- Clinical Potential of Catechol-O-Methyltransferase (COMT) Inhibitors as Adjuvants in Parkinsonʼs DiseaseCNS Drugs, 1994
- Improved Therapy of Parkinsonʼs Disease with Tolcapone, a Central and Peripheral COMT Inhibitor with an S-Adenosyl-L-Methionine-Sparing EffectClinical Neuropharmacology, 1994
- Effects of COMT inhibitors on striatal dopamine metabolism: a microdialysis studyBrain Research, 1992
- Extracellular Concentrations of Dopamine and Metabolites in the Rat Caudate After Oral Administration of a Novel Catechol‐O‐Methyltransferase Inhibitor Ro 40–7592Journal of Neurochemistry, 1992
- Rationale for Selective COMT Inhibitors as Adjuncts in the Drug Treatment of Parkinson's DiseaseBasic & Clinical Pharmacology & Toxicology, 1990
- New selective COMT inhibitors: useful adjuncts for Parkinson's disease?Trends in Pharmacological Sciences, 1989
- Properties of novel effective and highly selective inhibitors of catechol-O-methyltransferaseLife Sciences, 1988